Scientific Program | Emirates Haematology Conference 2022 | EHC

Download Program

Click on the session name for more details about the session

Thursday, March 24, 2022

Time	Program
02:00 PM - 04:00 PM	Pre-Conference \| Workshop by BiologixFerriprox® in the Management of Iron Overload Pre-Conference \| Workshop by Biologix Thursday, March 24, 2022 at 02:00 PM - 04:00 PM Details : Ferriprox® in the Management of Iron Overload Chairperson : Fatheya Al Khaja United Arab Emirates Topics : UK experience in Beta Thalassemia Iron Overload Management Paul Telfer United Kingdom 02:00 PM - 02:40 PM UAE experience in the management of severe iron overload (DFP monotherapy vs Combination) & Discussion Hani Dwedar United Arab Emirates 02:40 PM - 03:00 PM Adult Case Presentation & Discussion Hazzaa Al Zahrani Saudi Arabia 03:00 PM - 03:20 PM Pediatric Case Presentation & Discussion Yasser Wali Oman 03:20 PM - 03:40 PM Adult Case Presentation & Discussion Amar Lal United Arab Emirates 03:40 PM - 04:00 PM Close x
04:00 PM - 04:25 PM	Industry Symposium by Novo NordiskN8-GP (turoctocog alfa pegol; Esperoct): An extended half-life recombinant factor VIII molecule for patients with haemophilia A Industry Symposium by Novo Nordisk Thursday, March 24, 2022 at 04:00 PM - 04:25 PM Topics : N8-GP (turoctocog alfa pegol; Esperoct): An extended half-life recombinant factor VIII molecule for patients with haemophilia A Maria Elisa Mancuso Italy 04:00 PM - 04:25 PM Close x
04:30 PM - 04:55 PM	Industry Symposium by MSDAntifungal prophylaxis in high-risk patients with hematological malignancies Industry Symposium by MSD Thursday, March 24, 2022 at 04:30 PM - 04:55 PM Topics : Antifungal prophylaxis in high-risk patients with hematological malignancies Dionysis Neofytos Switzerland 04:30 PM - 04:55 PM Close x
05:00 PM - 05:25 PM	Industry Symposium by RocheDLBCL: Where do we stand in 2022? Industry Symposium by Roche Thursday, March 24, 2022 at 05:00 PM - 05:25 PM Topics : DLBCL: Where do we stand in 2022? Amar Lal United Arab Emirates 05:00 PM - 05:25 PM Close x
05:30 PM - 06:25 PM	Industry Symposium by NovartisASH Updates in SCD & Cardiovascular Risk in PV Industry Symposium by Novartis Thursday, March 24, 2022 at 05:30 PM - 06:25 PM Chairperson : Mahmoud Marashi United Arab Emirates Topics : ASH Updates in SCD Deepa Manwani United Arab Emirates 05:30 PM - 05:55 PM Cardiovascular Risk in PV Hadeel Ammar United Arab Emirates 06:00 PM - 06:25 PM Close x
06:30 PM - 06:55 PM	Industry Symposium by BMS 1Management of transfusion-dependent thalassemia: Unmet needs and novel therapies Industry Symposium by BMS 1 Thursday, March 24, 2022 at 06:30 PM - 06:55 PM Topics : Management of transfusion-dependent thalassemia: Unmet needs and novel therapies Khaled Musallam United Arab Emirates 06:30 PM - 06:55 PM Close x
07:00 PM - 07:25 PM	Industry Symposium by SandozBiosimilars for treating lymphoma : Rixathon “Rituximab Biosimilar by Sandoz” Industry Symposium by Sandoz Thursday, March 24, 2022 at 07:00 PM - 07:25 PM Chairperson : Mahmoud Marashi United Arab Emirates Topics : Biosimilars for treating lymphoma: Rixathon “Rituximab Biosimilar by Sandoz” Jorgen Kristensen United Arab Emirates 07:00 PM - 07:25 PM Close x
07:30 PM - 07:55 PM	Industry Symposium by SanofiThe Era of MRD Negativity and it’s impact on MM Management & Isatuximab phase 3 pivotal clinical Trial IKEMA trial Industry Symposium by Sanofi Thursday, March 24, 2022 at 07:30 PM - 07:55 PM Topics : The Era of MRD Negativity and it’s impact on MM Management Arif Alam United Arab Emirates 07:30 PM - 07:40 PM Isatuximab phase 3 pivotal clinical Trial IKEMA trial Arif Alam United Arab Emirates 07:40 PM - 07:55 PM Close x
08:00 PM - 08:25 PM	Industry Symposium by AstraZenecaHow to Select BTKI for your Patient?... The luxury to choose Industry Symposium by AstraZeneca Thursday, March 24, 2022 at 08:00 PM - 08:25 PM Topics : How to Select BTKI for your Patient?... The luxury to choose Amar Lal United Arab Emirates 08:00 PM - 08:25 PM Close x
08:30 PM - 08:55 PM	Industry Symposium by BMS 2TDT.. What has changed? Industry Symposium by BMS 2 Thursday, March 24, 2022 at 08:30 PM - 08:55 PM Topics : TDT.. What has changed? Amar Lal United Arab Emirates 08:30 PM - 08:55 PM Close x

Friday, March 25, 2022

Time	Program
02:00 PM - 02:25 PM	Industry Symposium by Eli LillyIndolent lymphoproliferative disease Industry Symposium by Eli Lilly Friday, March 25, 2022 at 02:00 PM - 02:25 PM Topics : Indolent lymphoproliferative disease Toby A Eyre United Kingdom 02:00 PM - 02:25 PM Close x
02:30 PM - 02:55 PM	Industry Symposium by AstellasADMIRAL Study: The paradigm shift for R/R FLT3 mutated AML Patients Industry Symposium by Astellas Friday, March 25, 2022 at 02:30 PM - 02:55 PM Chairperson : Hani Osman United Arab Emirates Topics : ADMIRAL Study: The paradigm shift for R/R FLT3 mutated AML Patients Husni Al Hateeti United Arab Emirates 02:30 PM - 02:55 PM Close x
02:55 PM - 03:00 PM	Opening Remarks
03:00 PM - 04:20 PM	Session 1: Myeloid Disorders Session 1: Myeloid Disorders Friday, March 25, 2022 at 03:00 PM - 04:20 PM Chairperson : Salam Al Kindi Oman Mahmoud Marashi United Arab Emirates Murtadha Al-Khabori Oman Topics : Management of PV in 2022 Ayalew Tefferi United States 03:00 PM - 03:20 PM Diagnosis and Prognosis of AML in 2022 Michael Savona United States 03:20 PM - 03:40 PM Diagnosis, Prognosis and management of MDS including MDS-MPN Ayalew Tefferi United States 03:40 PM - 04:00 PM Treatment of AML in 2022, moving forward from 7+3 Michael Savona United States 04:00 PM - 04:20 PM Close x
04:25 PM - 04:40 PM	ALL Case Presentations ALL Case Presentations Friday, March 25, 2022 at 04:25 PM - 04:40 PM Topics : Case Presentation 1 Amar Lal United Arab Emirates 04:25 PM - 04:30 PM Case Presentation Faraz Khan United Arab Emirates 04:30 PM - 04:35 PM Case Presentation 2 Amar Lal United Arab Emirates 04:35 PM - 04:40 PM Close x
04:45 PM - 05:25 PM	Q&A - Meet the Experts (Day 1) Q&A - Meet the Experts (Day 1) Friday, March 25, 2022 at 04:45 PM - 05:25 PM Chairperson : Salam Al Kindi Oman Murtadha Al-Khabori Oman Mahmoud Marashi United Arab Emirates Topics : Q&A - Meet the Experts Ayalew Tefferi United States 07:10 PM - 07:50 PM Q&A - Meet the Experts Michael Savona United States 07:10 PM - 07:50 PM Q&A - Meet the Experts Amar Lal United Arab Emirates 04:45 PM - 05:25 PM Close x
05:30 PM - 05:55 PM	Industry Symposium by StemlineBlastic Plasmacytoid Dendritic Cell Neoplasm BPDCN (Disease state, History, Diagnosis and Novel therapies) Industry Symposium by Stemline Friday, March 25, 2022 at 05:30 PM - 05:55 PM Topics : Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN (Disease state, History, Diagnosis and Novel therapies) David Alan Rizzieri United States 05:30 PM - 05:55 PM Close x
05:55 PM - 06:20 PM	Industry Symposium by Abbvie BCL2i outcomes in high-risk CLL patients Industry Symposium by Abbvie Chairperson : Faraz Khan United Arab Emirates Topics : BCL2i outcomes in high-risk CLL patients Carolyn Owen Canada 05:55 PM - 06:20 PM Close x

Saturday, March 26, 2022

Time	Program
01:30 PM - 01:55 PM	Industry Symposium by MSD 2The management paradigm of cHL Industry Symposium by MSD 2 Saturday, March 26, 2022 at 01:30 PM - 01:55 PM Topics : The management paradigm of cHL Khalil Al Farsi Oman 01:30 PM - 01:55 PM Close x
02:00 PM - 02:25 PM	Industry Symposium by Amgen Key Highlights in Managing RRMM Industry Symposium by Amgen Topics : Key Highlights in Managing RRMM Amar Lal United Arab Emirates 02:00 PM - 02:25 PM Close x
02:30 PM - 02:55 PM	Industry Symposium by KyowaKirinCutaneous T-Cell Lymphomas : Overview and clinical considerations Industry Symposium by KyowaKirin Saturday, March 26, 2022 at 02:30 PM - 02:55 PM Topics : Cutaneous T-Cell Lymphomas : Overview and clinical considerations Wendy Osborne United Kingdom 02:30 PM - 02:55 PM Close x
03:00 PM - 03:45 PM	Session 2: Best of ASH Session 2: Best of ASH Saturday, March 26, 2022 at 03:00 PM - 03:45 PM Chairperson : Amar Lal United Arab Emirates Topics : Best of ASH in Lymphoma Ranjana Advani United States 03:00 PM - 03:45 PM Close x
03:50 PM - 05:10 PM	Session 3: Lymphoproliferative disorders I Session 3: Lymphoproliferative disorders I Saturday, March 26, 2022 at 03:50 PM - 05:10 PM Chairperson : Arif Alam United Arab Emirates Shahrukh Hashmi United Arab Emirates Faraz Khan United Arab Emirates Topics : How I treat Indolent lymphoma in 2022 Jeremy Abramson United States 03:50 PM - 04:10 PM Treatment of Aggressive B cell lymphoma in 2022 Jeremy Abramson United States 04:10 PM - 04:30 PM CAR T cells in lymphoma and ALL Jeremy Abramson United States 04:30 PM - 04:50 PM How I treat CNS lymphoma in 2022 Grzegorz Nowakowski United States 04:50 PM - 05:10 PM Close x
05:15 PM - 06:35 PM	Session 4: Lymphoproliferative disorders II Session 4: Lymphoproliferative disorders II Chairperson : Hassan Al Yaseen United Arab Emirates Kayane Mheidly United Arab Emirates Topics : How I treat relapsed Hodgkin lymphoma Grzegorz Nowakowski United States 05:15 PM - 05:35 PM Treatment of relapsed Follicular lymphoma in 2022 Grzegorz Nowakowski United States 05:35 PM - 05:55 PM Diagnosis and choice of CLL therapy in 2022, How do you select? Sameer Parikh United States 05:55 PM - 06:15 PM Complications of CLL and CLL therapy Sameer Parikh United States 06:15 PM - 06:35 PM Close x
06:40 PM - 06:50 PM	Challenging Case Presentation Challenging Case Presentation Saturday, March 26, 2022 at 06:40 PM - 06:50 PM Topics : Challenging Case Presentation Hassan Al Yaseen United Arab Emirates 06:40 PM - 06:50 PM Close x
06:50 PM - 07:10 PM	Lymphoma Case Presentations Lymphoma Case Presentations Saturday, March 26, 2022 at 06:50 PM - 07:10 PM Topics : Case Presentation 1 Amar Lal United Arab Emirates 06:50 PM - 06:55 PM Case Presentation Faraz Khan United Arab Emirates 06:55 PM - 07:00 PM Case Presentation 2 Amar Lal United Arab Emirates 07:00 PM - 07:05 PM Case Presentation Arif Alam United Arab Emirates 07:05 PM - 07:10 PM Close x
07:10 PM - 07:50 PM	Q&A - Meet the Experts (Day 2) Q&A - Meet the Experts (Day 2) Saturday, March 26, 2022 at 07:10 PM - 07:50 PM Chairperson : Kayane Mheidly United Arab Emirates Hassan Al Yaseen United Arab Emirates Arif Alam United Arab Emirates Amar Lal United Arab Emirates Shahrukh Hashmi United Arab Emirates Faraz Khan United Arab Emirates Topics : Q&A - Meet the Experts Ranjana Advani United States 06:15 PM - 06:55 PM Q&A - Meet the Experts Jeremy Abramson United States 06:15 PM - 06:55 PM Q&A - Meet the Experts Grzegorz Nowakowski United States 06:35 PM - 07:15 PM Q&A - Meet the Experts Sameer Parikh United States 06:35 PM - 07:15 PM Close x
07:55 PM - 08:20 PM	Industry Symposium by Janssen 1New Horizons in CLL management Industry Symposium by Janssen 1 Saturday, March 26, 2022 at 07:55 PM - 08:20 PM Topics : New Horizons in CLL management Carolina Moreno Spain 07:55 PM - 08:20 PM Close x
08:20 PM - 08:45 PM	Industry Symposium by Takeda 1Acquired Hemophilia: The Tawam Experience Industry Symposium by Takeda 1 Saturday, March 26, 2022 at 08:20 PM - 08:45 PM Topics : Acquired Hemophilia: The Tawam Experience Hani Osman United Arab Emirates 08:20 PM - 08:45 PM Close x
08:45 PM - 09:10 PM	Industry Symposium by Takeda 2Maximizing patients outcome in Gaucher Disease Industry Symposium by Takeda 2 Saturday, March 26, 2022 at 08:45 PM - 09:10 PM Topics : Maximizing patients outcome in Gaucher Disease Ayman Elhattab United Arab Emirates 08:45 PM - 09:10 PM Close x

Sunday, March 27, 2022

Time	Program
02:00 PM - 02:25 PM	Industry Symposium by Janssen 2Advances in Management of Newly Diagnosed Multiple Myeloma Industry Symposium by Janssen 2 Sunday, March 27, 2022 at 02:00 PM - 02:25 PM Topics : Advances in Management of Newly Diagnosed Multiple Myeloma Amar Lal United Arab Emirates 02:00 PM - 02:25 PM Close x
02:30 PM - 02:55 PM	Industry Symposium by AstraZeneca 2Beyond COVID 19 Vaccination: Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19 Industry Symposium by AstraZeneca 2 Sunday, March 27, 2022 at 02:30 PM - 02:55 PM Chairperson : Mahmoud Marashi United Arab Emirates Topics : Beyond COVID 19 Vaccination: Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19 Mustaqeem Siddiqui United Arab Emirates 02:20 PM - 02:55 PM Close x
03:00 PM - 04:20 PM	Session 5: Plasma Cell Disorders Session 5: Plasma Cell Disorders Sunday, March 27, 2022 at 03:00 PM - 04:20 PM Chairperson : Ahmad Alhuraiji Kuwait Mustaqeem Siddiqui United Arab Emirates Topics : What are the important investigations in the new cases of myeloma and how do you follow up the case including MRD Jesus San-Miguel Spain 03:00 PM - 03:20 PM Is there still a role for ASCT in 2022 Morie Gertz United States 03:20 PM - 03:40 PM Can myeloma be cured in the era of new therapies? Jesus San-Miguel Spain 03:40 PM - 04:00 PM How I diagnose and treat amyloidosis in 2022 Morie Gertz United States 04:00 PM - 04:20 PM Close x
04:25 PM - 05:25 PM	Session 6: Bleeding Disorders Session 6: Bleeding Disorders Sunday, March 27, 2022 at 04:25 PM - 05:25 PM Chairperson : Amna Al Mehairi United Arab Emirates Hadeel Ammar United Arab Emirates Topics : VWD, approach to diagnosis and management Alice Ma United States 04:25 PM - 04:45 PM Investigation of patients with bleeding Alice Ma United States 04:45 PM - 05:05 PM Antiphospholipid syndrome, diagnosis and management Alice Ma United States 05:05 PM - 05:25 PM Close x
05:30 PM - 05:40 PM	Myeloma Case Presentations Myeloma Case Presentations Sunday, March 27, 2022 at 05:30 PM - 05:40 PM Topics : Case Presentation 1 Amar Lal United Arab Emirates 05:30 PM - 05:35 PM Case Presentation 2 Amar Lal United Arab Emirates 05:35 PM - 05:40 PM Close x
05:40 PM - 06:20 PM	Q&A - Meet the Experts (Day 3) Q&A - Meet the Experts (Day 3) Sunday, March 27, 2022 at 05:40 PM - 06:20 PM Chairperson : Amna Al Mehairi United Arab Emirates Ahmad Alhuraiji Kuwait Mustaqeem Siddiqui United Arab Emirates Hadeel Ammar United Arab Emirates Topics : Q&A - Meet the Experts Morie Gertz United States 05:25 PM - 06:05 PM Q&A - Meet the Experts Jesus San-Miguel Spain 05:25 PM - 06:05 PM Q&A - Meet the Experts Alice Ma United States 05:25 PM - 06:05 PM Q&A - Meet the Experts Amar Lal United Arab Emirates 05:40 PM - 06:20 PM Close x

*The scientific program is subject to change.